Author

e. Pellier

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:mouse· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

C. Bruge· 3 shared I. Richard· 3 shared M. BENABIDES· 3 shared X. Nissan· 3 shared J. Tournois· 2 shared L. hoch· 2 shared N. Bourg· 2 shared A. Bigot· 1 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

C. Bruge

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Identification of bazedoxifene for the treatment of LGMD R2 by high throughput screening.

C. Bruge, N. Bourg, E. PELLIER, J. Tournois, J. Polentes, M. BENABIDES, N. Grossi, A. Bigot, A. Brureau, I. Richard, X. Nissan

This study identifies bazedoxifene as a potential treatment for LGMD R2 through high-throughput screening of drugs targeting dysferlin aggregation.

bioRxiv · Feb 28, 2024 · PreprintPharmacology & Toxicology

Skeletal muscle cells derived from induced pluripotent stem cells: a platform for limb girdle muscular dystrophies.

c. Bruge, M. GEOFFROY, M. Benabides, e. Pellier, L. hoch, I. Richard, X. Nissan

This paper describes a platform using human induced pluripotent stem cells to model limb girdle muscular dystrophies and demonstrates its utility in studying disease-specific phenotypes.

bioRxiv · May 8, 2022Cell Biology

Dual blockade of misfolded alpha-sarcoglycan degradation by bortezomib and givinostat combination

L. Hoch, N. Bourg, F. Degrugillier, C. Bruge, M. Benabides, E. Pellier, J. Tournois, G. Mahe, N. Maignan, J. Dawe, M. Georges, D. Papazian, N. Subramanian, S. Simon, P. Fanen, , X. Nissan

This study identifies givinostat as a potential therapeutic for LGMD R3 by inhibiting autophagy and enhancing bortezomib's effect on misfolded alpha-sarcoglycan degradation.

bioRxiv · Mar 16, 2022Pharmacology & Toxicology